Remove Biosimilars Remove Drug Development Remove Pharmaceutical Manufacturing
article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. and Europe.

article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Robert Barrie June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bayer’s Eylea is a heavyweight of the ophthalmic drug landscape, approved for a range of eye diseases. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmaceutical Technology Excellence Awards 2025: i3 Membrane

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? This flexibility is particularly beneficial for pharmaceutical manufacturers looking to upgrade their research and discovery processes without overhauling their entire systems. “Great thanks to Pharmaceutical Technology.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years. The 505(j) pathway is how you get a multisource generic.

article thumbnail

Navamedic signs agreement to acquire dne pharma

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Zambon gains Chinese regulatory authority approval for Fluimucil IV

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”?